Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Foghorn Therapeutics Inc. FHTX
$6.24
+$0.11 (1.71%)
На 18:03, 12 мая 2023
+172.44%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
225435672.00000000
-
week52high
18.12
-
week52low
4.51
-
Revenue
19208772
-
P/E TTM
-2501
-
Beta
2.15760300
-
EPS
-2.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мар 2023 г. в 12:00
Описание компании
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Overweight | 24 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 23 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 20 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 21 ноя 2022 г. |
| BMO Capital | Outperform | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Reine Allan | A | 90000 | 90000 | 26 янв 2023 г. |
| GOTTSCHALK ADRIAN | A | 280000 | 280000 | 26 янв 2023 г. |
| LaCascia Michael | A | 90000 | 90000 | 26 янв 2023 г. |
| Costa Carlos | A | 65000 | 65000 | 26 янв 2023 г. |
| Bellon Steven F. | A | 100000 | 100000 | 26 янв 2023 г. |
| Cavalie Fanny | A | 65000 | 65000 | 26 янв 2023 г. |
| Agresta Samuel | A | 60000 | 60000 | 26 янв 2023 г. |
| Lynch Thomas J. Jr. | A | 32000 | 32000 | 27 окт 2022 г. |
| GOTTSCHALK ADRIAN | D | 418925 | 40000 | 16 сент 2022 г. |
| GOTTSCHALK ADRIAN | A | 186479 | 40000 | 16 сент 2022 г. |
Новостная лента
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
GlobeNewsWire
09 ноя 2022 г. в 07:00
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for its FHD-286 program will be highlighted in a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting. The meeting will be held November 8–12, 2022, at the Boston Convention and Exhibition Center and virtually.
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 09:48
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of -3.33% and 30.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit
GlobeNewsWire
20 окт 2022 г. в 07:00
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the Company will present new data at Hanson Wade's 5th Annual Targeted Protein Degradation Summit. The Summit will be held in Danvers, Mass., on October 25–28, 2022. Foghorn is advancing its protein degradation platform and pipeline which includes FHD-609, a first-in-class, highly potent, and selective degrader of BRD9, for the treatment of synovial sarcoma and SMARCB1-loss tumors, and additional programs.
Foghorn Therapeutics: Selling For Less Than Cash Value
Seeking Alpha
10 окт 2022 г. в 17:27
Today, we put Foghorn Therapeutics in the spotlight for the first time. The company is developing several early stage drug candidates, and the stock trades currently for less than the net cash on the balance sheet.
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewsWire
01 сент 2022 г. в 16:05
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in upcoming investor conferences in September. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.